Skip to content
HealthyAgainDiet
← Back to Home
GLP 1 & Weight Loss Drugs

What Happens After June 29? The FDA Semaglutide Deadline Explained

9 min read min readBy Healthy Again Diet Team

Last updated: 2026-06-27

If you've been using compounded semaglutide to manage your weight or blood sugar, the next few days matter. June 29 is a regulatory deadline in the FDA's ongoing process of winding down compounded versions of semaglutide — the active ingredient in Ozempic and Wegovy. After that date, the rules around who can legally make and sell compounded semaglutide become significantly more restrictive.

This isn't a ban on GLP-1 medications. It's the end of a regulatory exception that was always meant to be temporary. Here's what the deadline actually means, who it affects, and what your options look like going forward.

Why Compounded Semaglutide Existed in the First Place

To understand why June 29 matters, you need to understand why compounded semaglutide existed at all.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking a hormone your gut releases after eating, slowing digestion and signaling fullness to your brain. Originally developed for type 2 diabetes (Ozempic), it was later approved at higher doses for chronic weight management (Wegovy). The results were remarkable enough to drive demand far beyond what the manufacturers — Novo Nordisk — could supply.

From 2022 through 2024, the FDA placed semaglutide on its drug shortage list. That designation matters legally: it triggers a provision that allows compounding pharmacies to make their own versions of the drug, even when a brand-name equivalent exists. Under normal circumstances, compounders cannot copy an FDA-approved drug. The shortage exception changed that.

Hundreds of compounding pharmacies, operating under either Section 503A (traditional patient-specific compounders) or Section 503B (larger outsourcing facilities producing for multiple prescribers), began offering compounded semaglutide injections and oral troches at a fraction of the branded price. Patients who couldn't get Ozempic or Wegovy, or couldn't afford it, gained access through these channels.

When the Shortage "Ended" — and Why That's Complicated

The FDA declared the semaglutide shortage resolved in early 2025, triggering a countdown for compounding pharmacies to stop making it.

That decision was immediately contested. Patient advocacy groups, compounding pharmacy associations, and some prescribers argued that "shortage resolved" was being applied too broadly — that access remained a real problem for patients who couldn't afford $1,000+ per month for branded versions even with insurance. Multiple legal challenges were filed seeking to delay or reverse the phase-out timeline.

The FDA's position remained firm: once a shortage is resolved, the legal basis for compounding the drug evaporates. The agency set phased deadlines for 503A and 503B pharmacies to wind down production, with additional comment periods built in to allow public and professional input before those deadlines became final.

June 29 is one of those input deadlines — the closing date for a public comment period on aspects of the phase-out. After it closes, the FDA finalizes guidance without further public input, and enforcement posture becomes clearer.

What June 29 Actually Changes

The comment deadline closing does not mean compounded semaglutide disappears overnight. Here's the realistic sequence:

For 503B outsourcing facilities (large-scale producers): These facilities have faced earlier, stricter deadlines. By late 2025, most major 503B producers were already required to stop shipping new compounded semaglutide. Some received temporary enforcement discretion extensions; those protections become harder to maintain as comment periods close.

For 503A traditional compounding pharmacies: These pharmacies compound for individual patients with a specific prescription. The rules here have been more nuanced — some narrow exceptions exist for personalized doses, specific patient needs not met by commercial products, or documented allergies to inactive ingredients. The comment period closing helps define where those narrow exceptions end.

For patients: If you are currently receiving compounded semaglutide through a telehealth platform or direct prescription, June 29 is the point at which your provider or pharmacy should give you a clear answer about what's next. Reputable operators have been planning for this transition. Silence or vague reassurances from your provider after this date is a yellow flag.

Who Is Most Affected

Patients using telehealth GLP-1 services: Companies like Hims & Hers, Ro, and dozens of smaller platforms built business models around compounded semaglutide. Some have pivoted to other GLP-1 medications (tirzepatide, for example, had its own shortage and regulatory timeline). Others have arranged supply chains for FDA-approved branded versions, sometimes at negotiated cash prices. You should have received communication from your platform about your transition path.

Patients paying out of pocket: The branded drugs remain expensive. Novo Nordisk has expanded savings programs; some commercial insurance plans now cover Wegovy for weight management. If cost was the reason you chose compounded, it's worth calling your insurer now with new diagnostic codes — coverage has expanded in the last year.

Patients using compounded oral semaglutide: The FDA never approved an oral form of semaglutide for compounding — compounded oral troches and capsules were always on shakier legal ground than injectable versions. These are likely to face even stricter enforcement.

Patients with documented needs: If you have a legitimate clinical reason that the commercial product doesn't address (a specific inactive ingredient allergy, a dosing requirement not available in commercial form), your prescriber can make that case. This is a narrow path, but it exists.

What the FDA Is Not Saying

A few things worth clarifying, because confusion in this space is rampant:

This is not a safety recall. The FDA is not saying compounded semaglutide was dangerous. The concern has always been regulatory — the legal basis for making it no longer exists once the shortage is resolved, not that the compound itself harmed patients.

This does not affect Ozempic or Wegovy. Novo Nordisk's branded products remain fully available and are unaffected by any of this.

This does not mean GLP-1 medications are going away. The category is expanding. Tirzepatide (Mounjaro/Zepbound), oral semaglutide (Rybelsus, though at lower doses than injectable), retatrutide, and other compounds are in various stages of approval. The FDA is tightening the compounding channel, not the drug class.

Your Options After June 29

If you're currently on compounded semaglutide, here are your realistic next steps:

Talk to your prescriber this week. Don't wait for your next scheduled appointment. Ask directly: "What is my transition plan after the compounding deadline?" A good provider will already have an answer. If they don't, that tells you something.

Check your insurance now. Wegovy received FDA approval for cardiovascular risk reduction in 2024, which significantly expanded the number of insurance plans required to cover it. Pull up your benefits portal or call your insurer and ask about GLP-1 coverage for your specific diagnosis codes (weight management vs. diabetes vs. cardiovascular risk).

Ask about patient assistance programs. Novo Nordisk's Victoza and Ozempic programs, along with the NovoCare savings card for Wegovy, have expanded. If your household income is below certain thresholds, you may qualify for substantially reduced cost.

Explore other GLP-1 options. If tirzepatide (Mounjaro/Zepbound) is not on shortage and your insurer covers it, it may be a viable alternative. It works on both GLP-1 and GIP receptors and has shown strong efficacy in trials. This is a conversation to have with your prescriber, not a unilateral switch.

Be cautious about "alternative" sources. After regulatory deadlines, gray-market and outright illegal versions of popular drugs tend to proliferate online. Research peptide sites, international online pharmacies, and social media sellers operating outside the regulatory framework carry real safety risks — contamination, incorrect dosing, and no recourse if something goes wrong. The FDA has issued multiple warnings about these sources.

The Bigger Picture: What This Signals About GLP-1 Access

The semaglutide compounding saga has exposed a structural problem in American drug pricing that the regulatory cleanup doesn't solve. The FDA is enforcing the rules as written — once a shortage ends, the compounding exception ends. But the underlying issue (a life-changing medication priced out of reach for most people without insurance or savings programs) didn't get resolved by the shortage declaration.

What we're likely to see over the next 12–18 months:

  • More aggressive litigation from compounding pharmacy associations challenging the shortage-resolved determination
  • Expanded insurance coverage as cardiovascular indications broaden the covered population
  • New GLP-1 entrants increasing competitive pricing pressure on Novo Nordisk and Eli Lilly
  • Potential Congressional action on drug pricing for obesity medications specifically

For now, the practical reality is that compounded semaglutide is being phased out, and June 29 is a meaningful step in that process. If you've been relying on it, this week is the week to get clarity.

What to Do Right Now

  1. Contact your prescriber today — ask specifically about your post-June-29 plan.
  2. Call your insurer — check current GLP-1 coverage with your exact diagnosis code.
  3. Review Novo Nordisk's patient assistance programs at NovoCare.com if cost is a barrier.
  4. Document your current dose and response — if you transition to a branded version, your prescriber needs this to titrate correctly.
  5. Monitor FDA.gov for updated enforcement guidance after the comment period closes.

The end of the compounding exception is not the end of GLP-1 access. But navigating what comes next requires getting ahead of it, not waiting to see what happens.

The information in this article is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your medications or treatment plan. Regulatory timelines and enforcement guidance can change — verify current status at FDA.gov.

Subscribe to our newsletter for weekly updates on GLP-1 research, clean eating strategies, and the latest in metabolic health — delivered straight to your inbox.

Stay ahead of what's changing in weight loss medicine

Weekly research-backed updates on GLP-1s, metabolic health, and clean eating — no fluff.